title: Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus.
abstract: We have previously shown that tight metabolic control by insulin therapy reduced thromboxane-dependent platelet activation in non-insulin-dependent diabetes mellitus (NIDDM) patients. The present study was undertaken to determine whether a similar effect could be obtained without switching diabetics in secondary failure to insulin treatment. For this purpose, we gave strict diet and exercise advise program and adjusted on a weekly basis the oral antidiabetic therapy (glipizide) that 26 patients with NIDDM had been given over the previous months. Basal measurements of urinary 11-dehydro-TXB2 and PAI-1 confirmed previous findings of enhanced levels of these parameters in NIDDM patients with macrovascular disease in comparison to age- and sex-matched controls. After 2-6 weeks, 16 patients achieved tight metabolic control associated with significant reduction of both thromboxane biosynthesis and PAI-1 levels; 10 patients remained in poor control and no significant decrease of both parameters was observed. We conclude that reduction of in-vivo platelet activation and PAI-1 antigen levels after metabolic improvement obtained by frequent reassessment of sulphonylurea therapy together with strict diet and exercise programs may have beneficial effects on the progression of diabetic micro- and macrovascular disease.
authors.affiliation: Department of Internal Medicine, University of Chieti, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Davì
authors.forename: M
authors.initials: M
authors.lastname: Belvedere
authors.forename: S
authors.initials: S
authors.lastname: Vigneri
authors.forename: I
authors.initials: I
authors.lastname: Catalano
authors.forename: C
authors.initials: C
authors.lastname: Giammarresi
authors.forename: S
authors.initials: S
authors.lastname: Roccaforte
authors.forename: A
authors.initials: A
authors.lastname: Consoli
authors.forename: A
authors.initials: A
authors.lastname: Mezzetti
mesh_terms: D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D005913:Glipizide / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000096:biosynthesis* / Q000652:urine
chemical_list: D007004:Hypoglycemic Agents; D017395:Plasminogen Activator Inhibitor 1; D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; D005913:Glipizide